Who Paid My Doc
David Grainger
Reproductive Endocrinology Wichita, KS Medical Doctor
NPI 1558372102 CMS profile 24884
9300 E 29Th St N, Ste 102, Wichita, KS 67226
General payments
$240,547
Research payments
$2,000
Ownership & investment interest
$0
Research they led as principal investigator
$378,943
Through program year 2025, David Grainger of Wichita, KS is reported in the CMS Open Payments database as having received $240,547 across 328 general payments and $2,000 in research payments paid to them. Separately, studies naming them as principal investigator received $378,943 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $93 | 4 | |
| 2024 | General | $164 | 7 | |
| 2023 | General | $375 | 17 | |
| 2022 | General | $13,059 | 19 | |
| 2021 | General | $39,098 | 32 | |
| 2021 | Research | $2,000 | 3 | |
| 2020 | General | $28,583 | 28 | |
| 2019 | General | $159,175 | 221 |
Beside peers
- David Grainger
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to David Grainger were reported at $93. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | David Grainger | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $159,175 | $196 | $77–$425 | $163 |
| 2020 | $28,583 | $81 | $35–$182 | $114 |
| 2021 | $39,098 | $102 | $43–$247 | $132 |
| 2022 | $13,059 | $139 | $62–$303 | $149 |
| 2023 | $375 | $141 | $65–$285 | $160 |
| 2024 | $164 | $144 | $65–$302 | $164 |
| 2025 | $93 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
331 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in Kansas
Bruce Tjaden
Reproductive Endocrinology · Wichita, KS
Kara Ehlers
Reproductive Endocrinology · Wichita, KS
Laura Tatpati
Reproductive Endocrinology · Wichita, KS
Dan Gehlbach
Reproductive Endocrinology · Olathe, KS
Kristin Holoch
Reproductive Endocrinology · Kansas City, KS
Perry Lin
Reproductive Endocrinology · Coffeyville, KS
Related records
Reproductive Endocrinology in Kansas
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Kansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.